Thursday, September 23, 2021
|
8:25 a.m. – 9:20 a.m. ET
|
Non-CME Product Theater Symposium (Breakfast provided to paid attendees)
Title: Advances in targeted therapy for AML: Efficacy and practical management of BCL-2 inhibitors
Speaker: Glen J. Peterson RN, DNP, ACNP - University of Colorado, Blood Disorders and Cell Therapies Center, Aurora, CO
Supported by AbbVie
|
9:25 a.m. – 9:35 a.m. ET
|
Welcome and Announcements
|
9:35 a.m. – 10:20 a.m. ET
|
ASCO Direct™ Highlights Gastrointestinal
Speaker: Laura Dawson, MD, Professor, Princess Margaret/UHN
Review the Gastrointestinal abstracts from ASCO, discuss the results of the study, and analyze the findings.
|
10:25 a.m. – 11:10 a.m. ET
|
ASCO Direct™ Highlights Melanoma
Speaker: Karim Saab, MD, Assistant Professor of Medicine, Hennepin Healthcare
Review the Melanoma abstracts from ASCO, discuss the results of the studies, and analyze the findings.
|
11:10 a.m. – 11:30 a.m. ET
|
Break With Exhibitors
|
11:30 a.m. – 12:15 p.m. ET
|
ASCO Direct™ Highlights Genitourinary
Speaker: Daniel Spratt, MD, Chairman, Department of Radiation Oncology, University Hospitals
1. Review the Geniturinary abstracts from ASCO 2. Discuss the results of studies 3. Analyze the findings
|
12:20 p.m. – 1:15 p.m. ET
|
Non-CME Product Theater Symposium (Lunch provided to paid attendees)
Title: A Treatment Option for Patients with Urothelial Carcinoma, in the Adjuvant Setting
Speaker: Amanda Nguyen, PharmD
Supported by Bristol Myers Squibb
|
1:15 p.m. – 2:00 p.m. ET
|
ASCO Direct™ Highlights Head and Neck
Speaker: Andrew Hope, MD, Associate Professor, Princess Margaret Cancer Center, University Health Network
Review the Head & Neck abstracts from ASCO, discuss the results of the study, and analyze the findings.
|
2:05 p.m. – 2:50 p.m. ET
|
ASCO Direct™ Highlights Lung
Speaker: Ashish Saxena, MD, PhD, Assistant Professor of Medicine, Weill Cornell Medicine
Review the Lung abstracts from ASCO, discuss the results of the study, and analyze the findings.
|
2:50 p.m. – 3:00 p.m. ET
|
Closing Announcements
|
3:00 p.m. – 3:55 p.m. ET
|
Non-CME Product Theater Symposium (Dinner provided to paid attendees)
Title: MONJUVI (Tafasitamab-cxix) For Use As Second-Line Therapy In Adult Patients With R/R DLBCL, In Combination With Lenalidomide
Speaker: Mark Davis, PA-C
Supported by Incyte Corporation
|
4:30 p.m. – 5:30 p.m. ET
|
Networking Session
BACK TO TOP
|
Friday, September 24, 2021
|
7:55 a.m. – 8:50 a.m. ET
|
Non-CME Product Theater Symposium (Breakfast provided to paid attendees)
Title: FDA-approved first-line monotherapy option in advanced NSCLC
Speaker: Lauren Welch, MSN, NP-C, AOCNP
Supported by Regeneron Sanofi Genzyme
|
8:55 a.m. – 9:05 a.m. ET
|
Welcome and Announcements
|
9:05 a.m. – 9:50 a.m. ET
|
ASCO Direct™ Highlights Breast
Speaker: Aarti Bhardwaj, MD, Assistant Professor, Mount Sinai Health System
Review the Breast abstracts from ASCO, discuss the results of the study, and analyze the findings.
|
9:55 a.m. – 10:40 a.m. ET
|
Understanding Radiation Oncology
Speaker: Maitry Patel, CCPA, Physician Assistant, University Health Network
Provide an overview of Radiation Oncology and introduce audience to the nuances of Radiation Oncology.
|
10:45 a.m. – 11:05 a.m. ET
|
Break With Exhibitors
|
11:05 a.m. – 11:50 a.m. ET
|
ASCO Direct™ Highlights Myeloma
Speaker: Joseph Mikhael, MD, Professor, Translational Genomics Research Institute (TGen)
The most pertinent and practice changing abstracts from ASCO regarding myeloma will be presented and discussed.
|
12:00 p.m. – 12:55 p.m. ET
|
Non-CME Product Theater Symposium (Lunch provided to paid attendees)
Supported by Abbvie Pharmaceuticals
|
12:55 p.m. – 1:40 p.m. ET
|
ASCO Direct™ Highlights Lymphoma
Speaker: David Hughes, PharmD, Clinical Pharmacy Manager, Boston Medical Center
This session will present Lymphoma abstracts from the ASCO meeting.
|
1:40 p.m. – 2:00 p.m. ET
|
Break With Exhibitors
|
2:00 p.m. – 2:45 p.m. ET
|
ASCO Direct™ Highlights Leukemia
Speaker: Sangmin Lee, MD, Assistant Professor, Weill Cornell Medicine
This session will present Leukemia abstracts from the ASCO meeting.
|
2:45 p.m. – 3:15 p.m. ET
|
APAO Membership Update, Awards, and Closing Announcements
|
3:20 p.m. – 4:15 p.m. ET
|
Non-CME Product Theater Symposium (Dinner provided to paid attendees)
Title: PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement
Speaker: Jacqueline Weatherly, PA-C
Supported by Incyte Corporation
BACK TO TOP
|
Saturday, September 25, 2021
|
7:45 a.m. – 8:40 a.m. ET
|
Non-CME Product Theater Symposium (Breakfast provided to paid attendees)
Title: ERLEADA: For the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Speaker: Ralph V. Boccia, MD, FACP
Supported by Janssen
|
8:45 a.m. – 8:55 a.m. ET
|
Welcome and Announcements
|
8:55 a.m. – 9:45 a.m. ET
|
Billing and Coding
Speaker: Michael Powe, Vice President, Reimbursement & Professional Advocacy, American Academy of PAs
Payment policy for PAs and other health professionals continues to undergo a rapid transformation. Understanding can assist in positioning PAs to maximize their reimbursement and clinical value to employers and navigate the world of value-based reimbursement.
This session will alert PAs to the latest reimbursement and coverage policy trends and changes in Medicare policy scheduled for implementation in 2022. PAs will also gain knowledge about how to minimize concerns about billing mistakes that could lead to allegations of fraud and abuse.
|
9:50 a.m. – 10:40 a.m. ET
|
Adverse Events Related to Immunotherapy: A Focus on Immune Checkpoint Inhibitors
Speaker: Melinda Weber, DNP, APN, AOCN, C., Director of Care Transformation/Charge APN Skin & Sarcoma, Hackensack Meridian Health
1. Review the current indications for immune checkpoint inhibitors(ICI) therapy in oncology 2. Implement strategies for early recognition and prompt intervention to address immunotherapy related toxicity 3. Apply principles of immunotherapy rechallenge in patients with prior toxicity 4. Construct a patient care plan for monitoring and treating rare and late immunotherapy related adverse events to minimize morbidity and mortality
|
10:45 a.m. – 11:05 a.m. ET
|
Break With Exhibitors
|
11:05 a.m. – 11:55 a.m. ET
|
New Drug Approvals & Indications for Oncology
Speakers: David Hughes, PharmD, Clinical Pharmacy Manager, Boston Medical Center, and Jasmine Patel, PharmD, Clinical Pharmacy Specialist - Hematology/Oncology, Boston Medical Center
Oncology is rapidly changing with new drugs to improve outcomes of patients with cancer. These drugs can have novel mechanisms of action and many of them are targeted to specific mutations found on the cancer. With novel therapies, becomes new challenges for APPs as initiation and toxicity management can be complex. This session will overview 8 new drugs that have been approved in the last year. It will review the drug specifics itself, as well as the trial that led to the FDA approval and some key areas to focus in on for optimal toxicity management. Disease states included are lung cancer, prostate cancer, multiple myeloma, follicular lymphoma, and diffuse large B cell lymphoma (DLBCL)!
|
12:00 p.m. – 12:55 p.m. ET
|
Non-CME Product Theater Symposium (Lunch provided to paid attendees)
Title: Clinical Cases in Polycythemia Vera: When to Intervene With Jakafi® (ruxolitinib) | Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea
Speaker: Amber Essenmacher, PA-C, MMS
Supported by Incyte Corporation
|
12:55 p.m. – 1:50 p.m. ET
|
Sickle Cell Update and Pain Management
Speakers: Erik Summers, MD, CMO, Wake Forest Baptist Medical Center; and Jena Coltrane, NP-C, FNP- Pain & Addiction Medicine, Atrium Health- Wake Forest Baptist Health
The speakers will discuss inpatient sickle cell disease along with treatment options. They will also present their recent project on reducing inpatient stays in the sickle cell population.
|
1:50 p.m. – 2:10 p.m. ET
|
Break With Exhibitors
|
2:10 p.m. – 3:25 p.m. ET
|
Panel Discussion: Burnout
Moderator: Maitry Patel, CCPA, Physician Assistant, University Health Network Panelists: Eric Tetzlaff, MHS, PA-C, DFAAPA, Assistant Professor/Academic Clinician, Fox Chase Cancer Center; Joseph Mikhael, MD, Professor, Translational Genomics Research Institute (TGen); Aisling Barry, MD, Staff Radiation Oncologist, Princess Margaret Hospital; and Alisha DeTroye, MMS, PA-C, DFAAPA, Director of Advanced Practice-PAs, Director of Advanced Practice-PAs
Discuss burnout within healthcare, discuss strategies to combat and prevent burnout, and consider future sequela.
|
3:25 p.m. – 3:35 p.m. ET
|
Closing Announcements
|
3:40 p.m. – 4:35 p.m. ET
|
Non-CME Product Theater Symposium (Dinner provided to paid attendees)
Title: Stand Strong Against Platelet Destruction With TAVALISSE: A Patient's ITP Treatment Journey
Speaker: Kirollos Hanna, PharmD, BCOP, RPH
Supported by Rigel Pharmaceuticals
BACK TO TOP
|
Sunday, September 26, 2021
|
8:45 a.m. – 9:40 a.m. ET
|
Non-CME Product Theater Symposium (Breakfast provided to paid attendees)
Title: Simplify with Hemady
Speaker: Jaime Román III, MPAS, PA-C, Physician Assistant Senior, Texas Oncology – Plano West
Supported by Acrotech Biopharma
|
9:45 a.m. – 9:55 a.m. ET
|
Welcome and Announcements
|
9:55 a.m. – 10:55 a.m. ET
|
ASCO Direct™ Highlights Central Nervous System Tumors
Speaker: Alisha DeTroye, MMS, PA-C, DFAAPA, Director of Advanced Practice-PAs, Director of Advanced Practice-PAs
1. Review the abstracts from ASCO 2. Discuss the results of studies 3. Analyze the findings
|
11:00 a.m. – 11:50 a.m. ET
|
The Role of Social Work in the Post-Transplant Patient
Speaker: Kristy Katsetos, MSW, LICSW, Clinical Oncology Social Worker, Dana-Farber Cancer Institute
1. Review the issues/complications post-transplant patients face 2. Discuss the resources available to patients and family 3. Review the psychosocial techniques that can help the patient and family
|
11:55 a.m. – 12:45 p.m. ET
|
Survivorship Clinic
Speaker: Zana Correa, NP, Nurse Practitioner, Memorial Sloan-Kettering Cancer Center
1. Review the criterion for a survivorship clinic 2. Discuss the common issues/barriers with creating a clinic 3. Review the benefits to practice and patient/family
|
12:55 p.m. – 1:50 p.m. ET
|
Non-CME Product Theater Symposium (Lunch provided to paid attendees)
Title: In Adult and Pediatric Patients 12 Years and Older with Chronic GVHD, Intervene with Jakafi® (ruxolitinib) At the First Sign of Initial Systemic Treatment Failure
Speaker: Linda Perry, MS, PA-C
Supported by Incyte Corporation
|
1:50 p.m. – 2:45 p.m. ET
|
To Treat or Not to Treat: Considerations for Elderly Oncology
Speaker: Jennie Goble, PA-C, Physician Assistant, Mayo Clinic
The prevalence of cancer rises with age but so does the number of comorbidities. This session will review the methods to determine if a patient is fit to receive intensive cancer therapy. Predictive models for chemotherapy toxicity will be reviewed. Specific medication toxicity in elderly and unique considerations will be discussed. A team based decision making approach for elderly oncology patients will also be emphasized.
|
2:45 p.m. – 3:05 p.m. ET
|
Break With Exhibitors
|
3:05 p.m. – 4:25 p.m. ET
|
Panel Discussion: Oncology and Beyond: Alternative Roles for PAs in Oncology
Moderator: Jeremy Heinerich, PA-C, APP, Clinical Director, Mount Sinai Hospital Panelists: Patti Cuartas, PA-C, MBA, FACHE, Executive Director and Associate CMIO, Mount Sinai Health System; Maura Polansky, PA-C, Associate Professor, George Washington University; Dayne Alonso, PA-C, Chief Operating Officer/Chief Physician Assistant, Heme Onc Call; Zlata Janicijevic, MSc,PA-C, CCPA, Physician Assistant Emergency, Sunnybrook Health Science Centre; Deborah Yolin, PA-C, VP Clinical Operations, Ready; Heather Hylton, MS, PA-C, FASCO, DFAAPA, Learning and Development Lead/Director of Advanced Practice Providers, K Health; and John Katsetos, PA-C
1. Review the options available to APPs in oncology 2. Discuss the pathways for the different roles 3. Discuss resources available to assist with transition
|
4:25 p.m. – 4:35 p.m. ET
|
Closing Announcements
|
4:40 p.m. – 5:35 p.m. ET
|
Non-CME Product Theater Symposium (Dinner provided to paid attendees)
Title: Clinical management and dose modifications with an immunomodulatory treatment in relapsed/refractory multiple myeloma
Speaker: Patricia Mangan
Supported by Bristol Myers Squibb
BACK TO TOP
|